对《从那他珠单抗转换为芬戈莫德治疗多发性硬化症：来自奥地利多发性硬化症治疗登记处的真实数据》的更正
Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
作者信息
Guger Michael, Enzinger Christian, Leutmezer Fritz, Kraus Jörg, Kalcher Stefan, Kvas Erich, Berger Thomas
机构信息
Clinic for Neurology 2, Med Campus III, Kepler University Clinic, Krankenhausstrasse 9, 4021, Linz, Austria.
Department of Neurology, Medical University of Graz, Graz, Austria.
出版信息
J Neurol. 2019 Nov;266(11):2678. doi: 10.1007/s00415-019-09535-2.
PMID:31531765
Abstract
The original version of this article unfortunately contained a mistake. First and last names of the authors were interchanged. The correct author names are given below.
摘要
很遗憾，本文的原始版本存在一处错误。作者的姓和名被互换了。正确的作者姓名如下所示。
相似文献
1
Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.对《从那他珠单抗转换为芬戈莫德治疗多发性硬化症：来自奥地利多发性硬化症治疗登记处的真实数据》的更正
J Neurol. 2019 Nov;266(11):2678. doi: 10.1007/s00415-019-09535-2.
2
Correction to: Comment on "Efficacy of a single intra-articular injection of ultra-high molecular weight hyaluronic acid for hip osteoarthritis: a randomized controlled study".对《单次关节腔内注射超高分子量透明质酸治疗髋骨关节炎的疗效：一项随机对照研究》评论的更正
Eur J Orthop Surg Traumatol. 2018 Aug;28(6):1253. doi: 10.1007/s00590-018-2180-4.
3
Correction to: Distal radius fluoroscopic skyline view: extension-supination versus flexion-supination.对《桡骨远端透视天际线视图：伸展旋后与屈曲旋后》的更正
Eur J Orthop Surg Traumatol. 2019 Jul;29(5):1161. doi: 10.1007/s00590-018-02361-8.
4
Real-life clinical use of natalizumab and fingolimod in Austria.在奥地利，那他珠单抗和芬戈莫德的真实临床应用。
Acta Neurol Scand. 2018 Feb;137(2):181-187. doi: 10.1111/ane.12864. Epub 2017 Nov 20.
5
Correction to: Fear of heights in virtual reality saturates 20 to 40 m above ground.对《虚拟现实中离地20至40米高处的恐高症》的勘误
J Neurol. 2019 Sep;266(Suppl 1):88. doi: 10.1007/s00415-019-09420-y.
6
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.多发性硬化症中从那他珠单抗转换为芬戈莫德：一项法国前瞻性研究。
JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.
7
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.那他利珠单抗停药后，芬戈莫德对比干扰素β/那他珠单抗治疗多发性硬化症的疗效。
Brain. 2015 Nov;138(Pt 11):3275-86. doi: 10.1093/brain/awv260. Epub 2015 Sep 11.
8
Correction to: Development and validation of a classification algorithm to diagnose and differentiate spontaneous episodic vertigo syndromes: results from the DizzyReg patient registry.对《用于诊断和鉴别自发性发作性眩晕综合征的分类算法的开发与验证：来自DizzyReg患者登记处的结果》的更正
J Neurol. 2020 Dec;267(Suppl 1):168. doi: 10.1007/s00415-020-10293-9.
9
Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis.
Expert Rev Clin Pharmacol. 2016 Apr;9(4):541-546. doi: 10.1586/17512433.2016.1145053. Epub 2016 Feb 21.
10
Correction to: Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management-Single-Center Experience.对《肝细胞癌伴骨转移：发病率、预后意义及治疗——单中心经验》的勘误
J Gastrointest Cancer. 2017 Dec;48(4):390. doi: 10.1007/s12029-017-0009-8.
Zotero 插件